Trials / Completed
CompletedNCT03123692
NBMI - Clinical Study on COPD
A Randomised, Placebo-controlled, Blinded, Cross-over, Pilot Study to Explore Safety and Efficacy of NBMI Treatment of Patients With Mild, Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- EmeraMed · Industry
- Sex
- All
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A pilot study to explore safety of the treatment with the antioxidant and metal chelator NBMI in COPD patients. Investigational product: NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide Indication: Mild, moderate and severe COPD with bronchitis A randomised, two arm, double-blind, placebo-controlled, cross-over, once daily for 14 days pilot study in subjects with COPD with bronchitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emeramide | Lipophilic, membrane passing Metal chelator and anti oxidant |
| DRUG | Placebo | 14 days treatment with placebo |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2018-05-30
- Completion
- 2018-06-30
- First posted
- 2017-04-21
- Last updated
- 2021-03-05
Source: ClinicalTrials.gov record NCT03123692. Inclusion in this directory is not an endorsement.